Wojciech Jurczak
A5102788725- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Monoclonal and Polyclonal Antibodies Research
- Viral-associated cancers and disorders
- Lung Cancer Treatments and Mutations
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- CNS Lymphoma Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Cutaneous lymphoproliferative disorders research
- Biosimilars and Bioanalytical Methods
- PI3K/AKT/mTOR signaling in cancer
- Gastrointestinal Tumor Research and Treatment
- Chemotherapy-induced cardiotoxicity and mitigation
- Multiple Myeloma Research and Treatments
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
- Cancer-related gene regulation
- Protein Degradation and Inhibitors
- Multiple and Secondary Primary Cancers
- Epigenetics and DNA Methylation
The Maria Sklodowska-Curie National Research Institute of Oncology
2019-2025
National Institute of Oncology
2021-2024
Jagiellonian University
2013-2023
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2023
Memorial Sloan Kettering Cancer Center
2015-2023
Columbia University Irving Medical Center
2023
The Ohio State University
2023
Northwestern University
2023
Mansoura University
2023
Saint Vincent Hospital
2023
Bruton's tyrosine kinase (BTK) is a mediator of the B-cell–receptor signaling pathway implicated in pathogenesis B-cell cancers. In phase 1 study, ibrutinib, BTK inhibitor, showed antitumor activity several types non-Hodgkin's lymphoma, including mantle-cell lymphoma.
Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth survival of malignant B lymphocytes. In a phase 1 study, idelalisib, an orally active selective PI3Kδ inhibitor, showed antitumor activity in patients with previously treated indolent non-Hodgkin's lymphomas.
Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma.We conducted open-label, multicenter, randomized phase 3 trial involving patients with previously untreated stage III or IV classic lymphoma, in which 664 were assigned to receive brentuximab vedotin, doxorubicin, vinblastine, dacarbazine (A+AVD) 670 bleomycin, (ABVD). The primary end point was modified progression-free survival (the time progression, death,...
Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured R-CHOP. Polatuzumab vedotin an antibody-drug conjugate targeting CD79b, which ubiquitously expressed on the surface malignant B cells.We conducted a double-blind, placebo-controlled, international phase 3 trial to evaluate modified regimen R-CHOP (pola-R-CHP), in vincristine was replaced polatuzumab vedotin, as...
PURPOSE Ibrutinib has shown activity in non–germinal center B-cell diffuse large lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) untreated DLBCL. PATIENTS AND METHODS Patients were randomly assigned at a one-to-one ratio to (560 mg per day orally) R-CHOP or placebo R-CHOP. The primary end point was event-free survival (EFS) the intent-to-treat (ITT) population activated (ABC) DLBCL...
Peripheral T-cell lymphomas (PTCLs) represent a diverse group of non-Hodgkin with poor prognosis and no accepted standard care for patients relapsed or refractory disease. This study evaluated the efficacy tolerability belinostat, novel histone deacetylase inhibitor, as single agent in PTCL.Patients confirmed PTCL who experienced progression after ≥ one prior therapy received belinostat 1,000 mg/m(2) daily 30-minute infusions on days 1 to 5 every 21 days. Central assessment response used...
Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comparing and ibrutinib in patients with chronic lymphocytic leukemia (CLL).
PURPOSE Epcoritamab is a subcutaneously administered CD3xCD20 T-cell–engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20 + B cells. Single-agent epcoritamab previously demonstrated potent antitumor activity in dose escalation across B-cell non-Hodgkin lymphoma subtypes. PATIENTS AND METHODS In the dose-expansion cohort of phase I/II study (ClinicalTrials.gov identifier: NCT03625037 ), adults with relapsed or refractory large and at least two prior...
PURPOSE Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was evaluated in this global, multicenter, randomized, open-label, phase III study patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). METHODS Eligible patients, aged ≥ 18 years R/R CLL, were randomly assigned 1:1 centrally and stratified by del(17p) status, Eastern Cooperative Oncology Group performance status score, number of prior lines therapy. Patients received acalabrutinib...
Purpose Venetoclax is an orally bioavailable B-cell lymphoma 2 inhibitor. US Food and Drug Administration European Medicines Agency approval for patients with 17p deleted relapsed/refractory chronic lymphocytic leukemia [del(17p) CLL] was based on results from 107 patients. An additional 51 were enrolled in a safety expansion cohort. Extended analysis of all patients, including the effect minimal residual disease (MRD) negativity outcome, now reported. Patients Methods Overall, 158 or...
In a multinational, phase 3, head-to-head trial, ibrutinib, Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, BTK inhibitor greater specificity, as treatment for relapsed or refractory chronic lymphocytic leukemia (CLL) small lymphoma (SLL). prespecified interim analyses, zanubrutinib superior to ibrutinib respect overall response (the primary end point). Data from the final analysis of progression-free survival are now available.
PURPOSE Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) historically showed inferior survival standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Phase II studies demonstrated that adding immunomodulatory agent lenalidomide to R-CHOP improved outcomes in ABC-type DLBCL. The goal global, phase III ROBUST study was compare (R2-CHOP) placebo/R-CHOP previously untreated, METHODS Histology cell-of-origin type...